Article citationsMore>>

Peterson, J.A., Schwartz, R.P., Mitchell, S.G., Agar, M.H., et al. (2010) Why Don’t Out-of-Treatment Individuals Enter Methadone Treatment Programmes? International Journal of Drug Policy, 21, 36-42.
https://doi.org/10.1016/j.drugpo.2008.07.004

has been cited by the following article:

• TITLE: Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine

  AUTHORS: Robert B. Raffa, Joseph V. Pergolizzi, Robert Taylor, Robert P. James, Mark Pirner

  KEYWORDS: Lofexidine, Clonidine, Opioid Withdrawal, Receptor Affinity, Alpha-2 Agonist

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.10 No.1, January 3, 2019

  ABSTRACT: Lucemyra? (lofexidine hydrochloride) has recently been approved by the US FDA for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. Lofexidine is an alpha-2 adrenoceptor agonist. However, the clinical attributes of lofexidine differ in advantageous ways from the classical alpha-2 adrenoceptor agonist clonidine. In the present study, we measured the receptor binding profile of lofexidine and clonidine in an effort to gain an insight into the clinical difference(s).